文献速递白血病

基于基因表达的可临床应用评分预测急性髓系白血病诱导治疗耐药

A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

研究在351例德国AML协作组注册的初诊强化治疗AML患者中,用NanoString平台验证PS29MRC评分预测诱导失败。PS29MRCdic以59%敏感性、77%特异性识别诱导失败,并可在ELN-2017各风险类别内改善风险分层;高龄患者中仅PS29MRCdic为独立预测因子。

要点

  • PS29MRCdic可识别诱导失败,敏感性59%、特异性77%、总体准确率72%。
  • PS29MRCdic高风险者中位总生存1.8年,低风险者4.3年。
  • 多因素分析中仅年龄和PS29MRCdic为难治病的独立预测因子。

核心结论

  • PS29MRC可作为识别高危AML患者的有效分类器,风险分层可在ELN-2017基础上进一步细化。

研究设计与样本

  • 研究在351例新诊断并接受强化治疗的AML患者中进行分析,患者来自德国AML协作组注册。
  • 采用广泛应用的NanoString平台建立PS29MRC的临床可用检测,并在较近期治疗队列中验证分类器。

主要发现

  • 作为连续变量,PS29MRC在预测诱导失败方面优于既往发表的风险模型。
  • 分类器与总生存强相关。
  • PS29MRCdic识别诱导失败的敏感性59%、特异性77%、总体准确率72%(OR 4.81;P=4.15×10-10)。
  • PS29MRCdic可在ELN-2017的每个风险类别内改善风险分类。
  • PS29MRCdic高风险者中位总生存1.8年,低风险者4.3年。

关键数值与推荐

  • PS29MRCdic识别诱导失败:敏感性59%、特异性77%、总体准确率72%(OR 4.81;P=4.15×10-10)。
  • PS29MRCdic高风险者中位总生存1.8年,低风险者4.3年。

临床怎么用

  • PS29MRCdic可用于初诊AML患者在ELN-2017基础上进一步识别诱导失败高危者。
  • 预测分类器可能有助于针对高危AML患者开展临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prediction of resistant disease at initial diagnosis of acute myeloid leukemia (AML) can be achieved with high accuracy using cytogenetic data and 29 gene expression markers (Predictive Score 29 Medical Research Council; PS29MRC). Our aim was to establish PS29MRC as a clinically usable assay by using the widely implemented NanoString platform and further validate the classifier in a more recently treated patient cohort. Analyses were performed on 351 patients with newly diagnosed AML intensively treated within the German AML Cooperative Group registry. As a continuous variable, PS29MRC performed best in predicting induction failure in comparison with previously published risk models. The classifier was strongly associated with overall survival. We were able to establish a previously defined cutoff that allows classifier dichotomization (PS29MRCdic). PS29MRCdic significantly identified induction failure with 59% sensitivity, 77% specificity, and 72% overall accuracy (odds ratio, 4.81; P = 4.15 × 10-10). PS29MRCdic was able to improve the European Leukemia Network 2017 (ELN-2017) risk classification within every category. The median overall survival with high PS29MRCdic was 1.8 years compared with 4.3 years for low-risk patients. In multivariate analysis including ELN-2017 and clinical and genetic markers, only age and PS29MRCdic were independent predictors of refractory disease. In patients aged ≥60 years, only PS29MRCdic remained as a significant variable. In summary, we confirmed PS29MRC as a valuable classifier to identify high-risk patients with AML. Risk classification can still be refined beyond ELN-2017, and predictive classifiers might facilitate clinical trials focusing on these high-risk patients with AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Moser C, Jurinovic V, Sagebiel-Kohler S, et al. A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia. Blood Adv. 2021. PMID: 34535016. doi:10.1182/bloodadvances.2021004814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。